국내 주의력결핍 과잉행동장애 아동 및 청소년에서 메타데이트CD의 임상증상 및 신경인지기능 개선 효과에 대한 개방 연구

다국어 초록 (Multilingual Abstract)

Objectives：This study aimed to investigate the efficacy and safety of Metadate CD (MCD) when given to Korean children and adolescents with attention-deficit hyperactivity disorder (ADHD). We also explored the effects of the drug on diverse neurocognitive functions.
Methods：Ninety-one subjects with ADHD (mean age 8.6±2.2 years) were recruited at 6 outpatient clinics in Seoul, Korea. We used the ADHD Rating Scale (ARS), Clinical Global Impression (CGI), and comprehensive attention test (CAT) to measure the drug?s effects.
Results： After 0.92±0.32mg/kg/day of MCD were administered for 57.4±7.6 days, there was a 48.5% reduction in the mean total ARS scores (p＜.001). Fifty-seven subjects (64.8%) showed either much improved or very much improved outcomes on the CGI-Improvement scale. The CGI-Severity scale also decreased from an average of 4.7 to an average of 2.9 (p＜.001). Errors and response time standard deviations of the CAT, sustained attention test-to-response tasks, the flanker test, and divided attention test scores decreased after treatment (p＜.05). The forward memory span of the spatial working memory test scores increased (p＜.05). Thirty-five patients (39.8%) experienced side effects, of which the most common were headache (14.8%), nausea (12.5%), and anorexia (9.1%).
Conclusion：This open-label study suggests that MCD is effective and safe in improving the symptoms and neurocognitive functions of Korean children and adolescents with ADHD.

목차 (Table of Contents)

• 서론
• 방법
• 결과
• 고찰
• 결론
• References

참고문헌 (Reference)

1 윤형준, "주의력결핍 과잉행동장애 아동에서 공존질환에 따른 OROS-Methylphenidate의 효과와 안전성" 대한소아청소년 정신의학회 19 (19): 147-155, 2008

2 유한익, "국내 아동 및 청소년 주의력 평가를 위한 종합주의력검사의 표준화 연구" 대한소아청소년 정신의학회 20 (20): 68-75, 2009

3 이승혜, "Variability of Response Time as a Predictor of Methylphenidate Treatment Response in Korean Children with Attention Deficit Hyperactivity Disorder" 연세대학교의과대학 50 (50): 650-655, 2009

4 Raz A, "Typologies of attentional networks" 7 : 367-379, 2006

5 Trommer BL, "The go-no go test in attention deficit disorder is sensitive to methylphenidate" 6 : 128-131, 1991

6 Scheres A, "The effect of methylphenidate on three forms of response inhibition in boys with AD/HD" 31 : 105-120, 2003

7 Han DH, "The effect of methylphenidate on Internet video game play in children with attention-deficit/hyperactivity disorder" W B SAUNDERS CO-ELSEVIER INC 50 : 251-256, 200905

8 Pliszka SR, "The Texas Children’s Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder" 45 : 642-657, 2006

9 김영신, "The Reliability and Validity of Kiddie-Schedule for Affective Disorders and Schizophrenia-Present and Lifetime Version-Korean Version (K-SADS-PL-K)" 연세대학교의과대학 45 (45): 81-89, 2004

10 Fan J, "Testing the efficiency and independence of attentional networks" 14 : 340-347, 2002

11 Birmaher B, "Sustained release methylphenidate: pharmacokinetic studies in ADDH males" 28 : 768-772, 1989

12 Pelham WE Jr, "Sustained release and standard methylphenidate effects on cognitive and social behavior in children with attention deficit disorder" 80 : 491-501, 1987

13 Bedard AC, "Selective inhibition in children with attention-deficit hyperactivity disorder off and on stimulant medication" 31 : 315-127, 2003

14 Adler LD, "Review of medication adherence in children and adults with ADHD" 122 : 184-191, 2010

15 Conners CK, "Rating scales and checklists for child psychopharmacology" 21 : 809-843, 1985

16 Jonkman LM, "Perceptual and response interference in children with attention-deficit hyperactivity disorder, and the effects of methylphenidate" 36 : 419-429, 1999

17 Castellanos FX, "Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes" 3 : 617-628, 2002

18 Nigg JT, "Neuropsychologic theory and findings in attention-deficit/hyperactivity disorder: the state of the field and salient challenges for the coming decade" 57 : 1424-1435, 2005

19 Kim Y, "Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD" John Wiley & Sons 24 : 95-102, 200903

20 Rhodes SM, "Methylphenidate restores visual memory, but not working memory function in attention deficit-hyperkinetic disorder" 175 : 319-330, 2004

21 Mehta MA, "Methylphenidate improves working memory and set-shifting in AD/HD: relationships to baseline memory capacity" 45 : 293-305, 2004

22 Bedard AC, "Methylphenidate improves visual-spatial memory in children with attention deficit/hyperactivity disorder" 43 : 260-268, 2004

23 Anderson VR, "Methylphenidate controlled-delivery capsules (EquasymXL, Metadate CD): a review of its use in the treatment of children and adolescents with attention-deficit hyperactivity disorder" 8 : 319-333, 2006

24 Pentikis HS, "Methylphenidate bioavailability in adults when an extended-release multiparticulate formulation is administered sprinkled on food or as an intact capsule" 41 : 443-449, 2002

25 de Sonneville LM, "Methylphenidate and information processing. Part 1: Differentiation between responders and nonresponders; Part 2: Efficacy in responders" 16 : 877-897, 1994

26 Nass RD, "Evaluation and assessment issues in the diagnosis of attention deficit hyperactivity disorder" 12 : 200-216, 2005

27 김의정, "Efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder" PERGAMON-ELSEVIER SCIENCE LTD 31 : 210-216, 200701

28 Riccio CA, "Effects of stimulants on the continuous performance test (CPT): implications for CPT use and interpretation" 13 : 326-335, 2001

29 송동호, "Effects of Methylphenidate on Quantitative EEG of Boys with Attention-deficit Hyperactivity Disorder in Continuous Performance Test" 연세대학교의과대학 46 (46): 34-41, 2005

30 Faraone SV, "Effect of stimulants on height and weight: a review of the literature" 47 : 994-1009, 2008

31 Guy W, "ECDEU Assessment Manual for Psychopharmacology" US Dept Health, Education, and Welfare publication 1976

32 Brams M, "Duration of effect of oral long-acting stimulant medications for ADHD throughout the day" 26 : 1809-1825, 2010

33 Konrad K, "Differential effects of methylphenidate on attentional functions in children with attention-deficit/hyperactivity disorder" 43 : 191-198, 2004

34 Ridderinkhof KR, "Delta plots in the study of individual differences: new tools reveal response inhibition deficits in AD/Hd that are eliminated by methylphenidate treatment" 114 : 197-215, 2005

35 Pietrzak RH, "Cognitive effects of immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder" 30 : 1225-1245, 2006

36 Konrad K, "Clinical evaluation of subjective and objective changes in motor activity and attention in children with attention-deficit/hyperactivity disorder in a double-blind methylphenidate trial" 15 : 180-190, 2005

37 Biederman J, "Attention-deficit/hyperactivity disorder: a life-span perspective" 59 (59): 4-16, 1998

38 Kim B, "An observational multi-center study for evaluation of efficacy, safety and parental satisraction of methylphenidate-OROS in children with ADHD" 16 : 279-285, 2005

39 Hanisch C, "Age-dependent neuropsychological deficits and effects of methylphenidate in children with attention-deficit/hyperactivity disorder: a comparison of pre- and grade-school children" 111 : 865-881, 2004

40 DuPaul GJ, "ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretations" The Guilford Press 1998

41 Dirksen SJ, "A postmarketing clinical experience study of Metadate CD" 18 : 371-380, 2002

42 Haessler F, "A pharmacokinetic study of two modified-release methylphenidate formulations under different food conditions in healthy volunteers" 46 : 466-476, 2008

43 Biederman J, "A naturalistic 10-year prospective study of height and weight in children with attention-deficit hyperactivity disorder grown up: sex and treatment effects" 157 : 635-640, 2010

44 Greenhill LL, "A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder" 109 : 39-, 2002

45 Swanson JM, "A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study)" 113 : e206-e216, 2004